Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(50%)

Phase Distribution

Ph phase_1
1
50%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
Phase 1Safety & dosage
1(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(1)
Terminated(1)

Detailed Status

Terminated1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
50.0%
Most Advanced
Phase 1

Trials by Phase

Phase 11 (100.0%)

Trials by Status

terminated150%
completed150%

Recent Activity

0 active trials
Showing 2 of 2
terminatedphase_1

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

NCT05194735
completed

Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs

NCT05292859

Clinical Trials (2)

Showing 2 of 2 trials
NCT05194735Phase 1

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Terminated
NCT05292859

Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs

Completed

All 2 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
2